Genelux (GNLX) Net Equity Issued and Repurchased (2023 - 2026)
Genelux's (GNLX) quarterly Net Equity Issued and Repurchased came in at $18.5 million in Q1 2026, up 93.92% year-on-year from $9.6 million in Q1 2025, and up 93.92% quarter-over-quarter from $9.6 million in Q1 2025.
Genelux (GNLX) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Genelux's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- On a quarterly basis, Net Equity Issued and Repurchased rose 93.92% year-over-year to $18.5 million in Q1 2026; TTM through Mar 2026 was $18.5 million, a 93.61% increase from a year earlier, with the FY2025 full-year figure at $9.6 million, down 65.5% from the prior year.
- Net Equity Issued and Repurchased advanced to $18.5 million in Q1 2026 per GNLX's latest filing, from $9.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $18.5 million in Q1 2026 and bottomed at $15000.0 in Q4 2024.
- The 4-year median for Net Equity Issued and Repurchased is $8.3 million (2023), against an average of $8.9 million.
- Biggest YoY gain for Net Equity Issued and Repurchased was 93.92% in 2026; the steepest drop was 93.92% in 2026.
- Year by year, Net Equity Issued and Repurchased stood at $3.5 million in 2023, then sank by 99.57% to $15000.0 in 2024, then jumped by 63586.67% to $9.6 million in 2025, then surged by 93.92% to $18.5 million in 2026.
- Per Business Quant, the three latest GNLX Net Equity Issued and Repurchased figures stand at $18.5 million (Q1 2026), $9.6 million (Q1 2025), and $15000.0 (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 141.90 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 18.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.53 Mn |
| Mar 31, 2026 | 18.53 Mn |
| Mar 31, 2025 | 9.55 Mn |
| Mar 31, 2025 | 9.55 Mn |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.50 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 14.50 Mn |
| Mar 31, 2023 | 14.50 Mn |